WO2005054281A3 - Proteína nmb1125 y su uso en formulaciones farmaceuticas - Google Patents

Proteína nmb1125 y su uso en formulaciones farmaceuticas Download PDF

Info

Publication number
WO2005054281A3
WO2005054281A3 PCT/CU2004/000015 CU2004000015W WO2005054281A3 WO 2005054281 A3 WO2005054281 A3 WO 2005054281A3 CU 2004000015 W CU2004000015 W CU 2004000015W WO 2005054281 A3 WO2005054281 A3 WO 2005054281A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
formulations
nmb1125
antigen
protein nmb1125
Prior art date
Application number
PCT/CU2004/000015
Other languages
English (en)
French (fr)
Other versions
WO2005054281A2 (es
Inventor
Feyt Rolando Pajon
Nieto Gerardo Enrique Guillen
Garcia Gretel Sardinas
Nunez Lazaro Hiram Betancourt
Serra Lila Rosa Castellanos
Negrin Yasser Perera
Diaz Darien Garcia
Perez Olivia Niebla
Menendez Evelin Caballero
Blanco Sonia Gonzalez
Original Assignee
Ct Ingenieria Genetica Biotech
Feyt Rolando Pajon
Nieto Gerardo Enrique Guillen
Garcia Gretel Sardinas
Nunez Lazaro Hiram Betancourt
Serra Lila Rosa Castellanos
Negrin Yasser Perera
Diaz Darien Garcia
Perez Olivia Niebla
Menendez Evelin Caballero
Blanco Sonia Gonzalez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE602004023419T priority Critical patent/DE602004023419D1/de
Priority to EP04802607A priority patent/EP1693378B9/en
Priority to BRPI0417309-0A priority patent/BRPI0417309A/pt
Priority to AU2004294376A priority patent/AU2004294376A1/en
Priority to NZ547520A priority patent/NZ547520A/xx
Priority to AT04802607T priority patent/ATE444305T1/de
Application filed by Ct Ingenieria Genetica Biotech, Feyt Rolando Pajon, Nieto Gerardo Enrique Guillen, Garcia Gretel Sardinas, Nunez Lazaro Hiram Betancourt, Serra Lila Rosa Castellanos, Negrin Yasser Perera, Diaz Darien Garcia, Perez Olivia Niebla, Menendez Evelin Caballero, Blanco Sonia Gonzalez filed Critical Ct Ingenieria Genetica Biotech
Priority to PL04802607T priority patent/PL1693378T3/pl
Priority to US10/580,508 priority patent/US7691971B2/en
Priority to CA002547317A priority patent/CA2547317A1/en
Publication of WO2005054281A2 publication Critical patent/WO2005054281A2/es
Publication of WO2005054281A3 publication Critical patent/WO2005054281A3/es
Priority to NO20063020A priority patent/NO20063020L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Uso de un nuevo antígeno vacunal aplicado de manera preventiva o terapéutica contra enfermedades bacterianas, virales, cancerosas, o de otro origen. El objetivo técnico que se persigue es el desarrollo de formulaciones capaces de elevar el espectro protector de las vacunas ya existentes y extenderlo contra diferentes patógenos. Para lograr este objetivo se aisló e identificó la proteína NMB1125 como componente de las preparaciones de membrana externa de Neisseria meningitidis, capaz de inducir actividad bactericida. Adicionalmente, se clonó y expresó el gen codificante para la proteína NMB1125, la cual se purificó evaluándose luego su inmunogenicidad en biomodelos animales. El secuenciamiento de genes homólogos evidenció, por su elevado grado de conservación, su alto valor como antígeno inductor de una respuesta inmune cruzada cuando es presentado por diferentes vías. Las formulaciones resultantes de esta invención son aplicables en la industria farmacéutica como formulaciones vacunales para uso humano.
PCT/CU2004/000015 2003-12-03 2004-12-02 Proteína nmb1125 y su uso en formulaciones farmaceuticas WO2005054281A2 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP04802607A EP1693378B9 (en) 2003-12-03 2004-12-02 Protein nmb1125 and use thereof in pharmaceutical formulations
BRPI0417309-0A BRPI0417309A (pt) 2003-12-03 2004-12-02 proteìna nmb1125 e seu uso em formulações farmacêuticas
AU2004294376A AU2004294376A1 (en) 2003-12-03 2004-12-02 Protein NMB1125 and use thereof in pharmaceutical formulations
NZ547520A NZ547520A (en) 2003-12-03 2004-12-02 Protein NMB1125 and use thereof in pharmaceutical formulations
AT04802607T ATE444305T1 (de) 2003-12-03 2004-12-02 Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen
DE602004023419T DE602004023419D1 (de) 2003-12-03 2004-12-02 Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen
PL04802607T PL1693378T3 (pl) 2003-12-03 2004-12-02 Białko NMB1125 i jego zastosowanie w kompozycjach farmaceutycznych
US10/580,508 US7691971B2 (en) 2003-12-03 2004-12-02 Protein NMB1125 and use thereof in pharmaceutical formulations
CA002547317A CA2547317A1 (en) 2003-12-03 2004-12-02 Protein nmb1125 and use thereof in pharmaceutical formulations
NO20063020A NO20063020L (no) 2003-12-03 2006-06-28 Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20030285A CU23237A1 (es) 2003-12-03 2003-12-03 PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
CUCU2003/0285 2003-12-03

Publications (2)

Publication Number Publication Date
WO2005054281A2 WO2005054281A2 (es) 2005-06-16
WO2005054281A3 true WO2005054281A3 (es) 2005-08-04

Family

ID=40091628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2004/000015 WO2005054281A2 (es) 2003-12-03 2004-12-02 Proteína nmb1125 y su uso en formulaciones farmaceuticas

Country Status (18)

Country Link
US (1) US7691971B2 (es)
EP (1) EP1693378B9 (es)
KR (1) KR20060123759A (es)
CN (1) CN1890260A (es)
AR (1) AR047263A1 (es)
AT (1) ATE444305T1 (es)
AU (1) AU2004294376A1 (es)
BR (1) BRPI0417309A (es)
CA (1) CA2547317A1 (es)
CU (1) CU23237A1 (es)
DE (1) DE602004023419D1 (es)
ES (1) ES2334138T3 (es)
NO (1) NO20063020L (es)
NZ (1) NZ547520A (es)
PL (1) PL1693378T3 (es)
RU (1) RU2336900C2 (es)
WO (1) WO2005054281A2 (es)
ZA (1) ZA200604556B (es)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066791A1 (en) * 1999-04-30 2000-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
BR9910089A (pt) * 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066791A1 (en) * 1999-04-30 2000-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 30 March 2000 (2000-03-30), "Neisseria meningitidis serogroup A strain Z2491 complete genome; segment 4/7", XP002331526, retrieved from EBI accession no. EM_PRO:NMA4Z2491 Database accession no. NMA4Z2491 *
DATABASE UniProt [online] 1 October 2000 (2000-10-01), "Putative periplasmic protein.", XP002331525, retrieved from EBI accession no. UNIPROT:Q9JQZ2 Database accession no. Q9JQZ2 *
DATABASE UniProt [online] 5 July 2004 (2004-07-05), "Hypothetical protein NMB1125 (Hypothetical protein NMB1163).", XP002331527, retrieved from EBI accession no. UNIPROT:Q7DDH5 Database accession no. Q7DDH5 *
HERVÉ TETTELIN ET AL.: "Complete genome sequence of Neisseria meningitidis serogroup B strain MC58", SCIENCE, vol. 287, 10 March 2000 (2000-03-10), pages 1809 - 1815 *
PARKHILL, J. ET AL.: "Complete cDNA sequence of a serogroup A strain of Nesisseria meningitidis Z2491", NATURE, vol. 404, 2000, pages 502 - 506, XP000918875 *
PARKHILL, J. ET AL.: "Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491", NATURE, vol. 404, 2000, pages 502 - 506 *

Also Published As

Publication number Publication date
ES2334138T3 (es) 2010-03-05
CU23237A1 (es) 2007-09-26
DE602004023419D1 (de) 2009-11-12
BRPI0417309A (pt) 2007-09-11
ATE444305T1 (de) 2009-10-15
AR047263A1 (es) 2006-01-11
EP1693378B1 (en) 2009-09-30
NO20063020L (no) 2006-09-01
EP1693378B9 (en) 2010-05-19
AU2004294376A1 (en) 2005-06-16
CN1890260A (zh) 2007-01-03
RU2006123434A (ru) 2008-01-10
US20070218000A1 (en) 2007-09-20
CA2547317A1 (en) 2005-06-16
ZA200604556B (en) 2007-03-28
US7691971B2 (en) 2010-04-06
WO2005054281A2 (es) 2005-06-16
PL1693378T3 (pl) 2010-03-31
NZ547520A (en) 2009-07-31
KR20060123759A (ko) 2006-12-04
EP1693378A2 (en) 2006-08-23
RU2336900C2 (ru) 2008-10-27

Similar Documents

Publication Publication Date Title
Pasquevich et al. The protein moiety of Brucella abortus outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells in vivo, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis
PL372088A1 (en) Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
WO2006073431A3 (en) Avipox recombinants expressing foot and mouth disease virus genes
GB2458057A (en) Francisella strain for live vaccine
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease
WO2008082719A3 (en) Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
WO2004084935A3 (en) Francisella strain for live vaccine
NO20063017L (no) Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer
WO2003013598A3 (en) Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases
WO2003101482A3 (en) Liposome vaccine formulations for fin-fish
WO2005054281A3 (es) Proteína nmb1125 y su uso en formulaciones farmaceuticas
Silveira et al. Saccharomyces boulardii improves humoral immune response to DNA vaccines against leptospirosis
WO2003080112A3 (en) Imidazoquinolineamines as adjuvants in hiv dna vaccination
Farnós et al. The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice
WO2002072852A3 (en) Leporipox-based vector vaccines
WO2007112702A3 (es) Composición farmacéutica que comprende la proteína nmb0938
EP1074266A3 (en) Live attenuated bacteria for use in a vaccine
AR046921A1 (es) Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
WO2007087758A3 (es) Mimotopos de polisacáridos capsulares de neisseria meningitidis y formulaciones farmacéuticas
WO2005123121A3 (en) Use of dna molecule as vaccine adjuvant
Xue et al. A Novel Vaccine Candidate Against Fungal Infection
WO2007073706A3 (es) Péptidos miméticos de carbohidratos y su empleo en formulaciones farmacéuticas
WO2003011329A3 (de) Impfstoff für veterinäre und humanmedizinische prophylaxe und therapie von dermatophytosen
WO2007073705A3 (es) Composiciones farmacéuticas que contienen la proteína nma0939
WO2007112703A3 (es) Composición farmacéutica que comprende la proteína nmb0606

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480035877.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2547317

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004802607

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 547520

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020067010712

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/006266

Country of ref document: MX

Ref document number: 200604556

Country of ref document: ZA

Ref document number: 2006/04556

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004294376

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3646/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006123434

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2004294376

Country of ref document: AU

Date of ref document: 20041202

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004294376

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004802607

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007218000

Country of ref document: US

Ref document number: 10580508

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020067010712

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0417309

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10580508

Country of ref document: US